Oncology

The director of Clinical Research in Hematologic Malignancies at Levine Cancer Institute discussed adverse events in the CARTITUDE-1 trial.

The chief executive officer of Gamida Cell discussed upcoming research on 2 of their investigational agents, GDA-201 and omidubicel, for hematological malignancies.

Peter Riedell, MD, discussed the need for more research in mantle cell lymphoma and access to novel treatments, including CAR T-cell therapies.

The chief executive officer of Gamida Cell discussed the company's novel approach to cell proliferation.

C. Ola Landgren, MD, PhD, discussed the role of CAR T-cell therapies in multiple myeloma.

James Hoffman, MD, discussed the significance of the approval of ide-cel for patients with multiple myeloma.

Faith E. Davies, MD, discussed the potential of CAR T-cell therapies for the treatment of multiple myeloma.

At the 18-month follow-up, the CAR T-cell therapy led to early, deep, and durable responses with a manageable safety profile in patients with relapsed/refractory multiple myeloma.

Cynata Therapeutics' Ross Macdonald, PhD, discusses the company's pipeline and clinical-phase trials.

The director of the Mario Lemieux Center for Blood Cancers at UPMC Hillman Cancer Center discussed findings from the CARTITUDE studies.

Henry Chi Hang Fung, MD, from the Fox Chase Cancer Center, discusses axi-cel's potential in relapsed/refractory FL.

A panel of lymphoma experts discussed 2 recently approved treatments that are providing hope to patients with relapsed or refractory follicular lymphoma.

The FDA has paused the clearance of new ofranergene obadenovec batches while it reviews chemistry, manufacturing, and controls at various source locations.

A comparative analysis of the ZUMA-5 and SCHOLAR-5 trials revealed improvements in outcomes over currently available therapies.

Neurologic adverse effect associated with CAR T-cell therapies like ciltacabtagene autoleucel can be managed without long-term lasting effects, as long as they are caught and treated promptly in patients with relapsed/refractory multiple myeloma.

Long-term efficacy assessment of brexucabtagene autoleucel demonstrated high rates of MRD negativity and CR rates in pediatric and adolescent patients with relapsed or refractory B-cell acute lymphoblastic leukemia.

Bispecific T-cell engagers and chimeric antigen receptor T-cell therapies seem destined to move into earlier lines of therapy for multiple myeloma (MM), speakers at the European Hematology Association 2021 Virtual Congress said.

Treatment with the CAR T-cell therapy ciltacabtagene autoleucel significantly improved outcomes for patients with relapsed or refractory multiple myeloma when compared with conventional therapies.

Axicabtagene ciloleucel and tisagenlecleucel have been used mostly to treat patients with diffuse large B-cell lymphoma in the outpatient setting.

Intensified induction therapy with daratumumab in addition to cyclophosphamide, bortezomib, lenalidomide, and dexamethasone and bortezomib-augmented autologous stem cell transplant yielded robust responses in patients with ultra¬ high–risk multiple myeloma or primary plasma cell leukemia

The incidence of grade ≥2 cytokine release syndrome was lower in patients with relapsed or refractory multiple myeloma who received anakinra prophylaxis with orvacabtagene autoleucel, a B-cell maturation antigen-targeted CAR T-cell therapy.

Cytovia is exploring several NK cell-based therapies, an emerging class of cell therapies with high potential for fewer side effects and greater anti-tumor activity.

The phase 2 ZUMA-3 trial of brexucabtagene autoleucel showed that it is possible to intervene early to prevent some toxicity, said Bijal Shah, MD, associate member in the Department of Malignant Hematology at Moffitt Cancer Center.

The CAR T-cell therapy lisocabtagene maraleucel resulted in better efficacy versus standard of care with no new safety signals.

Larry D. Anderson Jr, MD, PhD, associate professor, Harold C. Simmons Comprehensive Cancer Center, discusses updated findings of the phase II KarMMa trial assessing ide-cel chimeric antigen receptor (CAR) T-cell therapy for treatment of adult patients with relapsed or refractory multiple myeloma after 4 or more prior lines of therapy.

C-CAR066 exhibited a favorable safety profile and promising efficacy in adult patients with relapsed/refractory B-cell non-Hodgkin lymphoma who failed with prior CD19 CAR T-cell therapy.

Ciltacabtagene autoleucel, an investigational BCMA-directed CAR-T therapy, sustained efficacy and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma.

Tisagenlecleucel led to high complete response rates that appear durable for patients with follicular lymphoma, prompting a regulatory submission later this year.

Dr. Munshi discusses the significance of the FDA approval of ide-cel in relapsed/refractory multiple myeloma, data from the KarMMa trial, which served as the basis for the approval, and next steps for CAR T-cell therapy in the field.

The combination of lifileucel and pembrolizumab was tolerable and led to responses for most patients with immune checkpoint inhibitor–naïve advanced melanoma.